News - Adasuve, Perjeta


Current filters:


Popular Filters

1 to 25 of 26 results

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA


US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Planned expansion of anti-psychotic drug throughout Europe


Austrian drugmaker AOP Orphan and privately held Spanish drugmaker Ferrer Internacional are expanding…

AdasuveAOP OrphanEuropeFerrer InternacionalMarkets & MarketingNeurologicalPharmaceutical

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production


Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Ferrer and Medivir join forces on Adasuve for Nordic markets


Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

Chugai launches Perjeta for breast cancer in Japan


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has launched the anti-cancer agent Perjeta (pertuzumab)…

Asia-PacificChugai PharmaceuticalMarkets & MarketingOncologyPerjetaPharmaceutical

FDA advisory panel backs new indication for Genentech's Perjeta


The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

UK NICE guidance says breast cancer drug Perjeta not value for money


The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…


Chugai gains Japanese approval for Perjeta and Bonviva


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Alexza deal with Teva sets stage for Adasuve, say analysts


USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical…

AdasuveAlexza PharmaceuticalAZ-002FinancialLicensingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Roche granted EU approval for Perjeta; board appointments


The European Medicines Agency has approved Swiss drug major Roche's (ROG: SIX) Perjeta (pertuzumab) for…


Growing patient population to drive Mexican breast cancer market


An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

San Antonio breast cancer meeting highlights


There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…


US oncologists' perceptions of Roche's Perjeta very promising


Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

New entrants from Roche and Novartis will drive breast cancer market


Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

FDA sets PDUFA date for Alexza's resubmission for Adasuve


Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Alexza rockets on re-submission of Adasuve NDA


USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) saw its shares soar 44.9% to close at $3.97 on Friday,…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

FDA backs Roche's personalized breast cancer therapy Perjeta


The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies


California, USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) revealed last week that it has received another…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved


US drug firm Alexza Pharmaceuticals (Nasdaq: ALXA) says that the US Food and Drug Administration will…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

1 to 25 of 26 results

Company Spotlight



Back to top